MET positive	Solid Tumor	MET positive	Solid Tumor	GST-HG16 Sensitive: C2 – Inclusion Criteria GST-HG16 Sensitive : C2	GST-HG16 Sensitive: C2 – Inclusion Criteria GST-HG16 Sensitive : C2
MET positive	Non Small Cell Lung Cancer	MET positive	Non Small Cell Lung Cancer	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2
MET positive	Squamous Cell Carcinoma of Head and Neck	MET positive	Squamous Cell Carcinoma of Head and Neck	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
MET positive	Lung Non-Squamous Non-Small Cell Cancer	MET positive	Lung Non-Squamous Non-Small Cell Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
MET positive	Lung Non-Small Cell Squamous Cancer	MET positive	Lung Non-Small Cell Squamous Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
MET positive	Non Small Cell Lung Cancer	MET positive	Non Small Cell Lung Cancer	erlotinib + LY2875358 Sensitive: C3 – Early Trials erlotinib + LY2875358 Sensitive : C3	erlotinib + LY2875358 Sensitive: C3 – Early Trials erlotinib + LY2875358 Sensitive : C3
MET positive	Gastric Cancer	MET positive	Gastric Cancer	c-MET-targeted CAR-T immunotherapy Sensitive: D – Preclinical c-MET-targeted CAR-T immunotherapy Sensitive : D	c-MET-targeted CAR-T immunotherapy Sensitive: D – Preclinical c-MET-targeted CAR-T immunotherapy Sensitive : D
MET positive	Gastric Cancer	MET positive	Gastric Cancer	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D

MET positive

Associations